Nachrichten zur Actinium Pharmaceuticals Inc. Aktie

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Solaris, Actinium, Ultra Clean, and SoundHound and Encourages Investors to Contact the Firm

NEW YORK, May 21, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights…

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Actinium Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - ATNM

NEW YORK, May 18, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been…

NRx Pharmaceuticals, Inc. (NRXP) Q1 2025 Earnings Call Transcript

…

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Solaris, Actinium, Bakkt, and Cerevel and Encourages Investors to Contact the Firm

NEW YORK, April 28, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights…

ATNM INVESTORS: Kirby McInerney LLP Reminds Actinium Pharmaceuticals, Inc. Investors of Important Deadline and Encourages Investors to Contact the Firm

NEW YORK, April 18, 2025 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP reminds investors that…

ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Actinium Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ATNM

NEW YORK, April 18, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law…

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Actinium Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ATNM

NEW YORK, April 12, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law…

ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Actinium Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ATNM

NEW YORK, April 09, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law…

NRx Pharmaceuticals, Inc. (NRXP) Q4 2024 Earnings Call Transcript

…

NRx Pharmaceuticals, Inc. (NRXP) Q3 2024 Earnings Call Transcript

…

Data from the phase 3 SIERRA trial of Iomab-B presented at the annual European Association of Nuclear Medicine (EANM) Congress 2024

Stockholm, October 25, 2024 – Immedica is pleased to announce that data from the Phase 3 SIERRA trial of Iomab-B…

NRx Pharmaceuticals, Inc. (NRXP) Q2 2024 Earnings Call Transcript

…

Immedica’s partner Actinium announces Iomab-B phase 3 SIERRA trial results in patients with TP53 mutation at the EHA 2024 Annual Congress

Stockholm, June 15, 2024 - Immedica’s partner Actinium Pharmaceuticals, Inc. announced results from the Phase 3 SIERRA trial of Iomab-B in…

NRx Pharmaceuticals, Inc. (NRXP) Q1 2024 Earnings Call Transcript

…

Actinium Pharmaceuticals advances in medical isotope production By Investing.com

Actinium Pharmaceuticals advances in medical isotope production…

Immedica’s partner Actinium presented four abstracts of Iomab-B at the 2024 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR®

Stockholm, February 27, 2024 – Immedica’s partner Actinium Pharmaceuticals, Inc. presented four abstracts at the 2024 Tandem Meetings | Transplantation…

dpa-AFX ProFeed